Oncolytics Biotech Inc T.ONC

Bayer looking for a "mid-size M&A transaction" in oncology

[Noteable]

June 13, 2023 - ' Roth agreed that $5 billion to $10 billion would be a good value estimate for a midsize M&A transaction.'

https://www.fiercepharma.com/pharma/bayer-needs-midsize-acquisition-reach-10b-cancer-drug-sales-goal-oncology-chief-says

As for modalities, Bayer has identified precision molecular oncology, next-generation immuno-oncology medicines and radioligand therapies as its top priorities.

Having an ambition to join the ranks of the top cancer drug makers motivates the organization. But to Roth, becoming a top oncology player isn’t just about the statistics but rather building a business to have a bigger impact on patient care.

In another boon to Bayer’s oncology ambitions, a pharma veteran with deep oncology experience just arrived as the helmsman of the entire Bayer group. Bill Anderson, most recently Roche’s pharma chief, officially became Bayer's CEO on June 1.

[Noteable]

" The deal would likely come with a later-stage drug, Bayer’s oncology chief Christine Roth said. The right deal would also fit in Bayer’s focus tumor types and potentially within its three pillars of treatment modalities, Roth added. Roth agreed that $5 billion to $10 billion would be a good value estimate for a midsize M&A transaction. But she also said she’s not

[Noteable]

Bayer's Chief Scientific Offiecer in oncology Christine Roth agreed that $5 billion to $10 billion would be a good value estimate for a midsize M&A transaction.

[Noteable]

Once again .. Bayer's Chief Scientific Offiecer in oncology Christine Roth agreed that $5 billion to $10 billion would be a good value estimate for a midsize M&A transaction. ONCY's Phase 3 ready platform technology positions ONCY's M&A acquisition value of between US$10-15 Billion.

[westcoast1000]

Thanks Noteable. These figures sound more relevant every day. Also Bayer wants to build up its immunology/oncology capacity and its precision medicine, IIRC. That screams ONCY. Roche and Bayer are both Swiss based. 

[Noteable]

As previously posted ..Bayer's Chief Scientific Offiecer in oncology Christine Roth agreed that $5 billion to $10 billion would be a good value estimate for a midsize M&A transaction.

[Noteable]

ONCY's late-stage phase 3 bio-platform technology in pelareorep addresses multiple unmet medical needs in the sought after oncology market space and is fairly valued for a M&A deal at between US$10 Billion to US$15 Billion.

[Noteable]

Should read : ONCY's late-stage phase 3 - ready bio-platform technology in pelareorep addresses multiple unmet medical needs in the sought after oncology market space and is fairly valued for a M&A deal at between US$10 Billion to US$15 Billion.

[Noteable]

And then there is Bayer's Chief Scientific Officer in oncology Christine Roth comment that conservatively $5 billion to $10 billion would be a good value estimate for a midsize M&A transaction.

[Noteable]

Looks like this needs repeating ... ' Roth agreed that $5 billion to $10 billion would be a good value estimate for a midsize M&A transaction.'

[fox7mf]

So Oncy goes from a $11b-$15b valuation to $5b-$10b? Let's start with getting the gd market cap up to $1b  or $2b.

[Noteable]

An independent opinion from a Big Biotech oncolcolgy chief scientific officer saying that a M&A valued between US$5 Billion and US$10 Billion is 'good vaue' for the acquiring Big Pharma company confirms what I have been saying for quite awhile.  This notwithstanding ONCY's fair value is between US$10 Billion and US$15 Billion, given the shift in time and the increased

[Noteable]

If Rigby and Parsons properly do their job, then ONCY is worth well more than US$15 Bilion, given that ONCY has 2 Phase 3 ready drugs and plenty of room for indication expansion.

[fox7mf]

Let's hope they do their jobs in a timely manner from this point on, because my patience is running thin.

[fox7mf]

So, how do we go from a $175m market cap to a $15b+ valuation? I mean in a timely manner, like before 2030.

[Buckhenry]

They might consult with Elizabeth  Holmes from theranos. She has plenty of free time for creative consulting I hear. 

[Lesalpes29]

What we don't know for sure is how many BP are interested. More than one we are in business! We wait. GL

[Noteable]

How? .... With an offer that the BOD can't refuse.

[fox7mf]

What I'm getting at, and it concerns me greatly, is how do we arrive at a $200+ a share buyout for a $2.75 a share biotech? Of course, keeping in mind that no one wants to spend many more months or years while MC tries to create value. I know Onc should be worth a truck load, but how would, say Roche, expect shareholders to sign off on deal worth $200 a share for what we currently trade at

[westcoast1000]

Fox, My theory, or rather long term dream: some Big pharma buys on third of the company through a new class of non trading shares for 1.5 bil. Our share price moves to reflect a now 4.5 bil market cap.  They own 1/3 of ONCY and the right to be our exclusive partner. Then ONCY and the BP let BP design the trials and we pay our share. After further results, the BP buys the company at a price

[fox7mf]

Are these type deals, structured as you suggested, often seen? Very interesting WC.

[13X2413]

It's obvious we're all hoping for a miracle. I have these fantasies too. This thing continues to frustrate everybody. Up and down like a yo yo.  Too much hype about buyout dreams starts to sound too pumpish to me. Settle down boys. 

[Buckhenry]

That's all these dreamers gave been doing for 3 loooong years and counting. They won't stop... like a druggie  they need their daily fix of dreaming.  Maybe time to take some anti anxiety pills dreamers. 

[westcoast1000]

Fox, In corporate mergers or takeovers, or in finance in general, creating a new class of non trading shares has often occurred although I cannot cite cases. I go on discussions with my corporate lawyer friends. I have also heard of big pharma taking a minority interest within a partnership, and then doing a buyout after more information is available that can serve as the basis for the final

[Lesalpes29]

Intriguing what is behind the actual pop on volume since monday. I think we will have something positive shortly. Not buying and not selling until we know. 

[Noteable]

How do we get from here to there? I have already answered that in my past posts.

[fox7mf]

A +$10b usd buyout would be a lot easier to see if....Coffey, Parsons and Rigby could create some shareholder value and get this baby to say, $40 per share by Sept. 

[Noteable]

If Bayer sees "good value" in an oncology M&A transaction between US$5 and $ 10 Billion, others see the same good value at a range between $10 and &15 Billion.

[fox7mf]

We all hope so, but it isn't happening at Oncy's current share price. Looks like we're in this for the long haul, while management attempts to improve the valuation. 

[Buckhenry]

For all those putting and putting.......... and putting out their buyout prices...... wish in one hand and poop in the other and see which one gets full first. 

[Noteable]

https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=35495533

[Lesalpes29]

A multiple billions buyout can come fast but we need BP interested. All the pieces seem to be in place to negotiate ... results, directors to deal with BP and in my opinion all the board members ready to sell. But the price could be too low for some actually. But I'm like you Fox... could take until the end of the year. 

[Noteable]

June 14, 2024 - "The [biopharma] industry is staring down a looming patent cliff like it’s a massive hurricane inching toward landfall. And the patent cliff not too far in the distance is set to be one of the most harrowing in history." With the industry facing this onslaught of challenges, pharma companies are battening the hatches through increased partnerships [M&A] and at

[Noteable]

Should read - June 14, 2023

[Noteable]

Pharma giant Bayer is launching a precision health unit. "We believe we can help consumers move from reactive to proactive aging, with individualized insights about their biological age at all stages of life," said Heiko Schipper, president of Bayer's consumer health division. Schipper pointed to Bayer's work with Edifice Health, a company that uses state-of-the-art

[Noteable]

Bayer sees "good value" in moving on M&A transactions of between US$5 Billion to US$10 Billion  And the list of Big Pharma companies looking to hit their M&A "sweet spot" of US$5 Billion to US$25 Billion is growing, particularly given the regulatory environment presented by the FTC rulings. Note also that the FTC announced that it will be reviewing the merger of

[Noteable]

Big Phamra is facing a looming patent cliff which will primarily be addressed by acquistions of eary- late stage biotechnology companies.  Faced with this looming patent cliff and need to expand their oncology pipelines Bayer, for example, sees "good value" in moving on M&A transactions of between US$5 Billion to US$10 Billion, while Big Pharma's M&A "sweet-spot

[Noteable]

Should read: "....M&A "sweet-spot" is U$5 Billion to US$25 Billion and US$1.5 Trillion in deal-making firepower."

[Noteable]

Did I mention that Big Pharma sees "good value" in moving on M&A transactions of between US$5 Billion to US$10 Billion? They are wishing to acquire "good value" at a lower value than they are worth.   And the list of Big Pharma companies looking to hit their M&A "sweet spot" of US$5 Billion to US$25 Billion is growing, particularly given the